Viewing Study NCT06623409



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06623409
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-09-30

Brief Title: Safety and Immunogenicity of V540B in Healthy Adults V540B-002
Sponsor: None
Organization: None

Study Overview

Official Title: A Phase 1 Randomized Double-Blind Comparator-Controlled Dose-Escalation Study to Evaluate the Safety Tolerability and Immunogenicity of V540B in Healthy Adults
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Researchers are looking for new ways to prevent cancers related to human papillomavirus HPV HPV is a common virus that can cause an infection There are many different types of HPV Most peoples immune system can fight HPV infection and it goes away without treatment For some people HPV infections can last longer and may cause cancer years later

A standard vaccine to prevent HPV-related cancers is GARDASIL9 G9 G9 protects against 9 types of HPV but it does not protect against other types of HPV The study vaccine called V540B is designed to protect against the same HPV types that G9 protects against plus other HPV types The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None